(2) after radiotherapy, the expression of the immune checkpoint molecule CEACAM1 was upregulated, and the CEACAM1 can inhibit the effector functions of TIL (Tumor infiltrates T cells), such as cytotoxicity and IFN-γ release[11]; and the treatment of anti-CEACAM1 can regulate the release of cytokines and activate the immune responses. The gene discussed is CEACAM1; the disease is neoplasm.